

Special Issue

Dopamine and Serotonin Receptors: Selective or Multitarget Ligands for the Treatment of Central Nervous System Diseases

Message from the Guest Editors

Dopamine and serotonin neurotransmitter pathways play important roles in regulating several physiological functions in the central nervous system and are altered in numerous diseases, including psychiatric and neurodegenerative disorders. An efficacious treatment strategy involves the discovery and development of ligands selectively targeting dopamine or serotonin receptor subtypes, with limited side effects (“magic bullets”). However, the multitarget or “magic shotgun” approach, combining dopamine and serotonin receptor systems, might produce improved results in the treatment of polyfactorial pathologies. Indeed, with respect to combined therapies, multitarget drugs may offer clear advantages, including reduced risk of drug interactions, more predictive pharmacokinetics, and better patient compliance. We invited you to submit original or review articles dealing with the discovery and/or development of subtype selective or multitarget ligands targeting dopamine and/or serotonin receptors potentially useful for the treatment of central nervous system diseases.

Guest Editors

Dr. Fabio Del Bello

School of Pharmacy, Medicinal Chemistry Unit, University of Camerino,
62032 Camerino, Italy

Dr. Wilma Quaglia

Medicinal Chemistry Unit, School of Pharmacy, University of Camerino,
62032 Camerino, Italy

Deadline for manuscript submissions

closed (25 March 2025)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/180896

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)